bioRxiv Science⌕ Search

Biology subjects

Aguilar-Aguilar, E.

Publications and source records attributed to Aguilar-Aguilar, E..

2 recordsLinked to original sources

Gut microbial ecosystems differ across metabolic and obesity phenotypes

Obesity is a heterogeneous condition comprising a continuum of phenotypes with various metabolic and inflammatory profiles. Metabolically healthy obesity (MHO) identifies individuals with obesity but a relatively preserved metabolic state. However, the criteria defining MHO remain inconsistent, and little is known about the gut microbiome (GM) features underlying this intermediate phenotype. Here, we aim to describe microbial structures contributing to metabolic health and disease. To do so, we analyzed the GM of 959 individuals classified as metabolically healthy non-obese (MHNO), MHO, metabolically unhealthy non-obese (MUNO), and metabolically unhealthy obese (MUO), using stool shotgun metagenomics. MHO subjects display intermediate anthropometric and biochemical profiles, with a GM composition and diversity in an in-between state among MHNO and MUO individuals. Network science analyses reveal that metabolic health, rather than obesity, drives microbial connectivity: MHNO and MHO individuals harbor more robust and functionally cohesive microbial networks, whose most influential nodes are focused toward SCFA production. In contrast, MUO and MUNO communities exhibit a dysbiotic state with reduced connectivity and increased influence of low-abundance, ectopic and potentially pro-inflammatory species resulting in a damaged, unstable microbial community network. These findings suggest that metabolic disorders disrupt microbial ecology beyond compositional shifts, emphasizing the need for systems-level approaches. Our findings show differences in microbial connectivity and association patterns across metabolic and obesity phenotypes, shedding light on how distinct microbial structures may contribute to metabolic health and disease.

bioinformatics↗

Non-responsive Celiac disease symptoms associated with microbiome network structure and function

Non-responsive celiac disease (NRCD) poses a challenge for clinicians due to the persistence of symptoms despite maintaining a gluten-free diet (GFD). This study investigated the gut microbiome, mucosal integrity, and metabolomic profiles of 39 NRCD patients to gain insights into the underlying mechanisms contributing to symptom persistence. Two distinct clusters of patients were identified based on clinical and demographic variables not influenced by gluten consumption. Cluster 1, labelled "Low-grade symptoms," displayed milder symptoms and lower inflammatory markers. In contrast, Cluster 2, named "High-grade symptoms," exhibited more severe gastrointestinal and extraintestinal symptoms, along with elevated inflammatory markers and increased intestinal permeability. Despite similar mucosal damage in both clusters, network analysis of the gut microbiome revealed specific microbial taxa with potential functional implications. Cluster 1 displayed a microbiome associated with immune homeostasis and gut barrier integrity, potentially lowering inflammation and symptom severity. In contrast, Cluster 2 had a distinct microbiome linked to lactate production, Th17 activation, possibly contributing to heightened inflammation and gastrointestinal symptoms. Metabolomic analysis revealed differential metabolites between clusters, particularly in amino acid metabolism pathways. Metabolites associated with specific symptoms were identified, implicating their potential role in symptom manifestation. Notably, vitamin D deficiency was observed in both clusters, suggesting its relevance in the context of NRCD. The study highlights the importance of the gut microbiome, mucosal integrity, and metabolic pathways in symptom persistence among NRCD patients. The associations between microbial-derived metabolites and symptom severity provide valuable insights into potential therapeutic targets. Further research is needed to validate these findings and develop targeted interventions for improving clinical outcomes in NRCD patients.

microbiology↗